Nektar Therapeutics
NKTR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $191,265 | $107,414 | $422,932 | $2,476,356 |
| - Cash | $44,252 | $35,277 | $88,227 | $25,218 |
| + Debt | $102,564 | $117,776 | $131,496 | $143,177 |
| Enterprise Value | $249,577 | $189,913 | $466,201 | $2,594,315 |
| Revenue | $98,427 | $90,122 | $92,055 | $101,907 |
| % Growth | 9.2% | -2.1% | -9.7% | – |
| Gross Profit | $67,741 | $53,478 | $70,420 | $77,010 |
| % Margin | 68.8% | 59.3% | 76.5% | 75.6% |
| EBITDA | -$86,697 | -$243,107 | -$323,872 | -$461,821 |
| % Margin | -88.1% | -269.8% | -351.8% | -453.2% |
| Net Income | -$118,961 | -$276,056 | -$368,198 | -$523,837 |
| % Margin | -120.9% | -306.3% | -400% | -514% |
| EPS Diluted | -8.68 | -21.79 | -29.51 | -42.9 |
| % Growth | 60.2% | 26.2% | 31.2% | – |
| Operating Cash Flow | -$175,709 | -$192,606 | -$304,007 | -$412,660 |
| Capital Expenditures | -$1,468 | -$865 | -$5,676 | -$14,989 |
| Free Cash Flow | -$177,177 | -$193,471 | -$309,683 | -$427,649 |